Semaglutide pill study for heart fat in diabetes after heart attack
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests if a daily semaglutide pill can reduce harmful fat around the heart in people with type 2 diabetes who had a heart attack 2 to 9 months ago. It aims to see if this treatment can improve heart health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older and have type 2 diabetes.
- You had a heart attack between 2 and 9 months ago.
- Your body mass index (BMI) is between 25 and 40.
- You are not currently using or have not recently used GLP-1 or DPP-4 diabetes medications.
- You do not have type 1 diabetes, severe heart failure, or kidney failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if an oral semaglutide pill can reduce liver fat and improve body composition in people who have had a liver transplant and have diabetes. It may help manage weight and blood sugar after transplant.
This study tests if a weekly injection (semaglutide) combined with an exercise program can help reduce fat stored in the heart and muscles in people with type 2 diabetes. It may improve how well your body handles sugar and lowers your risk for heart problems.
This trial studies whether the drug semaglutide can help people with heart failure who are overweight. It aims to see if the drug improves heart function and symptoms.
This study tests whether the diabetes medication semaglutide can reduce inflammation and improve blood vessel health in people with type 2 diabetes who have no significant heart artery blockages. If you have diabetes and are at moderate to high heart risk but haven't had heart problems, this could help understand the medicine's extra benefits beyond blood sugar control.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This study is testing whether a class of diabetes medicines called GLP-1 receptor agonists can help people with type 2 diabetes and coronary artery disease. If you have recently had a heart artery-opening procedure and are already taking another diabetes medicine called an SGLT2 inhibitor, this trial may be a good fit for you.
Hear when a new Diabetic Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.